Infliximab-induced autoantibodies: a multicenter study

Clinical Rheumatology

Volumn 35, Issue 2, 2016, Pages 325-332

  Vaz, João Luiz Pereira ^a   Fernandes, Vander ^b   Nogueira, Felipe ^c   Arnóbio, Adriano ^c   Levy, Roger A ^c,d,e  

^a FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF CUIABÁ   (Brazil)

^c UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO   (Brazil)

^d Centro de Imunoterapia de Ipanema CITIPA   (Brazil)

^e Rua Rodolfo Dantas 16/1004 ^*  (Brazil)

Author keywords

Autoantibodies; Biomarkers; Diagnostic tests; Infliximab; Pharmacovigilance

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INFLIXIMAB; ANTIRHEUMATIC AGENT;

ADULT; ANKYLOSING SPONDYLITIS; APOPTOSIS; ARTHRALGIA; ARTICLE; CENTROMERE; CHROMATIN; CONTROLLED STUDY; FEMALE; HEADACHE; HEP 2 CELL LINE; HUMAN; IMMUNOFLUORESCENCE; INFLAMMATORY BOWEL DISEASE; LONGITUDINAL STUDY; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OBSERVATIONAL STUDY; OPEN STUDY; PHASE 4 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RASH; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT DURATION; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED;

ANTIRHEUMATIC AGENTS; AUTOANTIBODIES; FEMALE; HUMANS; INFLIXIMAB; LONGITUDINAL STUDIES; MALE; MIDDLE AGED;

EID: 84958179998     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-015-3140-6     Document Type: Article

References (22)

1. Eriksson C, Rantapãã-Dahlqvist S, Sundqvist KG (2013) Changes in chemokines and their receptors in blood during treatment with TNF inhibitor infliximab in patients with rheumatoid arthritis. Scand J Rheumatol 42:260–265
2. Moulis G, Sommet A, Lapeyre-Mestre M, Montastruc JL (2014) Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database. Rheumatology (Oxford) 53:1864–1871
3. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F (2005) The effect of TNF alpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 14:931–937
4. De Bant M, Sibilia J, Le Löet X, Prouzeau S, Fautrel B, Marcelli C et al (2005) Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by anti- tumor necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7:R545–R551
5. Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeverbeke T (2008) Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNFα blockers. Clin Exp Rheum 26:401–407
6. Araújo-Fernández S, Ahijón-Lana M, Isenberg DA (2014) Drug-induced lupus: including anti-tumour necrosis factor and interferon induced. Lupus 23:545–553
7. Xiao X, Chang C (2014) Diagnosis and classification of drug-induced autoimmunity (DIA). J Autoimmun 48–49:66–72
8. Marzano AV, Vezzoli P, Crosti C (2009) Drug-induced lupus: an update on its dermatologic aspects. Lupus 18:935–940
9. Rubin RL (2015) Drug-induced lupus. Expert Opin Drug Saf 14:361–378
10. Shabana AA, El-Ghawet AE, Machaly SA, Hashim EMA, El-Kady BA, Shaat R (2009) Anti-chromatin and anti-histone antibodies in Egyptian patients with systemic lupus erythematosus. Clin Rheumatol 28:673–678
11. Pallotta P, Cianchini G, Ruffelli M, Puddu P (2006) Infliximab-induced lupus-like reaction in a patient with psoriatic arthritis. Rheumatology (Oxford) 45:116–117
12. Mountz JD, Wu J, Cheng J, Zhou T (1994) Autoimmune disease. A problem of defective apoptosis. Arthritis Rheum 37:1415–1420
13. Sibilia J (2002) Les Lupus induits par les medicaments. Rev Rheum 69:355–369
14. Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N (2004) Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 6:R535–R543
15. Bobbio-Palavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C (2004) Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 6:R264–R272
16. Eriksson C, Engstrand S, Sundqvist K-G, Rantapää-Dahlqvist S (2005) Autoantibody formation in patients with rheumatoid arthritis treated with anti- TNFα. Ann Rheum Dis 64:403–407
17. De Rycke L, Baeten D, Kruithof E, van den Bosch F, Veys EM, De Keyser F (2005) Infliximab, but not etanercept, induces IgM anti-double strand DNA autoantibodies as main antinuclear reactivity—biological and clinical implications in autoimmune arthritis. Arthritis Rheum 52:2192–2201
18. Nancey S, Blanvillain E, Parmentier B, Flourié B, Bayet C, Bienvenu J et al (2005) Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn’s disease. Inflamm Bowel Dis 11:986–991
19. Hoxha A, Ruffatti A, Grypiotis P, Podswiadek M, Botsios C, Fiocco U et al (2006) Gli autoanticorpi antinucleo, anti-dsDNA, anti-ENA nei pazienti con artrite reumatoide o spondilite anchilosante in trattamento con infliximab. Reumatismo 58:121–126
20. Viana VST, Carvalho JF, Moraes JCB, Saad CG, Ribeiro AC, Gonçalves C et al (2010) Autoantibodies in patients with psoriatic arthritis on anti-TNFα therapy. Rev Bras Reumatol 50:225–234
21. Hoffmann JHO, Hartmann M, Enk AH, Hadaschik EN (2011) Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. BJD 165:1355–1358
22. Vaz JLP, Andrade CAF, Pereira AC, Martins MFM, Levy RA (2013) Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus. Rev Bras Reumatol 53:358–364